JL
Insider
Jeffrey M Leiden
Executive ChairmanJeffrey M Leiden (Executive Chairman) filed 3 Form 4 reports in the trailing twelve months (1 purchase, 2 sales), most often in Vertex Pharmaceuticals Incorporated (VRTX). Across 1 priced purchase filing, the average 21-session return was -14.4% from execution and +3.2% from disclosure (delay-adjusted; derived). The largest single filing was $32.3M of VRTX (73,252 sh across 4 lots, as filed), executed Nov 13 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-14.4%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+3.2%
same 1 filings, from disclosure
Filings, ttm
3
1 buys · 2 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$61.0M
shares × price, as filed
Last traded
May 8
Filed May 11
Median ADV $756.7M across their filed names
Open performance→Volume by month
Buys $100K
Sells $60.9M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Not on file
1 filing
Sector per market data · by filing · past 12 months
Most traded names
VRTX
Vertex Pharmaceuticals Incorporated
VRTX · 0 buys · 2 sells
2 filings
ODTX
ODTX
ODTX · 1 buy · 0 sells
1 filing
Recent filings
ODTXPURCHASE
Odyssey Therapeutics, Inc.
View filing →
$100K5,000 sh × $20.00
Exec May 8
Filed May 11 · 8:35 PM ET VRTXSALE Vertex Pharmaceuticals Incorporated View filing → $28.7M
63,781 sh across 12 lots
Exec Dec 3 2025
Filed Dec 5 2025 · 5:30 PM ET VRTXSALE Vertex Pharmaceuticals Incorporated View filing → $32.3M
73,252 sh across 4 lots
Exec Nov 13 2025
Filed Nov 17 2025 · 5:30 PM ET